Treating penile cancer



most common symptoms of benign prostatic hypertrophy :: Article Creator

Your Questions Answered About Benign Prostatic Hyperplasia

An enlarged prostate—also known as benign prostatic hyperplasia (BPH)—is a natural sign of aging that affects half of all men over the age of 40. The good news is this condition does not increase your risk of developing prostate cancer. It can, however, disrupt your daily life by causing annoying and sometimes painful urination problems.

"Fortunately, for most patients, this condition is highly treatable and manageable with medical treatment," says Elisabeth Mulroy, MD, a urologist in the Division of Urology at University of Utah Health. "That's why it's good to recognize the symptoms and get help early on."

What's Happening Down There?

BPH symptoms are caused by the prostate (a gland just beneath the bladder), compressing the urethra (the tube that lets urine leave the bladder and the body). As men age, the walnut-sized prostate grows, which can result in urinary problems.

Common symptoms of BPH include:

  • Bladder obstruction, such as a slow stream of urine
  • Starting and stopping while urinating
  • Inability to empty your bladder completely
  • Bladder irritation or discomfort
  • Feeling an urgency to urinate
  • Sleepless nights caused by bathroom breaks
  • Inability to control your bladder
  • When symptoms arise, Mulroy encourages men to schedule a medical exam to explore underlying causes and treatment options. It's also important to discuss family history because genetics can be a risk factor for BPH.

    "If symptoms go untreated, it can result in decreased quality of life and urinary tract infections," Mulroy says. "In more severe cases, it may result in urinary retention with the need for catheterization or possible kidney dysfunction."

    What Are My Treatment Options?

    Your doctor may prescribe one or more types of medications, depending on your symptoms and the size of your prostate gland.

    Common treatment options include:

  • Alpha Blockers: This medication relaxes the prostate and bladder opening to allow better urine flow. Common medications include alfuzosin (Uroxatral) and tamsulosin (Flomax).
  • PDE5 Inhibitors: This medication relaxes the muscles in your bladder and prostate to reduce some of the symptoms of BPH. A common medication is tadalafil (Cialis).
  • 5-Alpha Reductase Inhibitors: This medication blocks hormones that can lead to prostrate growth. It can take up to six months to see results. Common medications are dutasteride and finasteride (Proscar).
  • Surgery: This option is usually considered when medications do not improve the symptoms or lose effectiveness. Surgery can also be considered when the patient wants to stop taking medications.  
  • Can Lifestyle Changes Help?

    As the old saying goes: An apple a day keeps the doctor away. Healthy living can significantly mitigate the effects of aging, including BPH. Here are some lifestyle changes that can help alleviate symptoms:

  • Eating whole foods and exercising regularly
  • Limiting beverage intake after dinnertime
  • Reducing alcohol and caffeine consumption
  • Avoiding certain medications that could trigger urinary problems
  • "It's so important to take care of ourselves as we age," Mulroy says. "A healthy lifestyle and annual health screenings can significantly improve health outcomes for men with BPH."


    Know About These 8 Myths Associated With Benign Prostate Conditions

    VERIFIED While some treatments for prostate conditions can impact sexual function, it is not inevitable. (Photo: Freepik) Did you know that not all prostate symptoms indicate a serious problem? Some urinary symptoms can be attributed to other factors, such as urinary tract infections or bladder issues.

    In the male reproductive system, the prostate is a small, walnut-sized gland that can become a topic of concern for men as they age. One often associates prostate-related problems with cancer, but benign prostate conditions -- such as benign prostatic hyperplasia (BPH) -- are common, and often misunderstood. Dr Niti Krishna Raizada, senior director, medical oncology and hemato-oncology at Fortis Hospitals, Richmond Road, Bangalore says there are numerous myths and misconceptions surrounding these conditions that can cause unnecessary anxiety and confusion.

    The expert debunks some of the common myths surrounding benign prostate conditions; read on.

    Myth 1: All prostate enlargement is cancer

    Fact: This is one of the most prevalent myths. In reality, benign prostatic hyperplasia (BPH) is a non-cancerous condition characterised by the enlargement of the prostate gland. BPH is common among aging men and is not associated with an increased risk of prostate cancer. While BPH can cause urinary symptoms, it is not a malignancy.

    Myth 2: Only older men experience benign prostate conditions

    Fact: While it is true that the risk of developing BPH increases with age, younger men can also be affected. Some men may experience symptoms of BPH in their 40s or even earlier. Although its prevalence rises with age, it is not exclusive to older individuals.

    Myth 3: Benign prostate conditions don't require treatment

    Fact: Some men believe that benign prostate conditions do not require treatment, as they are non-cancerous. While these conditions are not life-threatening, they can significantly impact a man's quality of life. Symptoms such as urinary frequency, urgency, weak urine flow, and nocturia can be bothersome and disruptive. Treatment options are available to alleviate these symptoms.

    Myth 4: Surgery is the only solution

    Fact: For BPH, there are various treatment approaches available. These range from lifestyle modifications to medications and minimally invasive procedures. Surgery is typically considered when other treatments have failed or in severe cases. Many men with BPH can effectively manage their symptoms without surgery.

    Myth 5: Sexual dysfunction is inevitable with prostate conditions

    Fact: Many fear prostate conditions will lead to erectile dysfunction or reduced sexual desire. While some treatments for prostate conditions can impact sexual function, it is not inevitable. With appropriate management, most men can preserve their sexual health while addressing their prostate issues.

    Myth 6: All prostate symptoms are a cause for concern

    Fact: Not all prostate symptoms indicate a serious problem. Some urinary symptoms can be attributed to other factors, such as urinary tract infections or bladder issues. While it's essential to consult a healthcare provider when experiencing new or bothersome symptoms, not all of them are indicative of prostate conditions or cancer.

    Myth 7: Prostate conditions are inevitable

    Fact: While the risk increases with age, not all men will experience symptoms or require treatment for BPH. Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can help reduce the risk and severity of these conditions.

    Myth 8: Only medications can relieve prostate symptoms

    Fact: While medications are commonly prescribed to alleviate BPH symptoms, there are other effective non-pharmacological approaches. Dietary modifications, exercise, and avoiding caffeine and alcohol can help improve urinary symptoms. Minimally invasive procedures and surgical options are also available for those who do not respond well to medication.


    Benign Prostatic Hyperplasia Market Size In 7MM Is Expected To Witness A Major Change In The Study Period 2019–2032, Estimates DelveInsight

    "The Benign Prostatic Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics"

    The Benign Prostatic Hyperplasia market report provides current treatment practices, Benign Prostatic Hyperplasia emerging drugs, market share of individual therapies, and current and forecasted 7MM Benign Prostatic Hyperplasia market size from 2019 to 2032. The report also covers current Benign Prostatic Hyperplasia treatment market algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

    Key Takeaways from the Benign Prostatic Hyperplasia Market Research Report

  • The increase in Benign Prostatic Hyperplasia (BPH) market size is a direct consequence of expected approval of emerging therapies and increasing Benign Prostatic Hyperplasia patient population in the 7MM.
  • Benign Prostatic Hyperplasia is highly prevalent among older men, with the risk increasing with age. By age 50, around 50% of men have some level of BPH, and this figure rises to 80% or more by age 80.
  • The leading companies working in the Benign Prostatic Hyperplasia Market include Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., and others.
  • Promising Benign Prostatic Hyperplasia Pipeline Therapies in the various stages of development include Tadalafil, Alpha1 Blocker, Tamsulosin OCAS, GV1001, Tamsulosin Hydrochloride Capsules, Silodosin and others.
  • September 2023: Dongkook Pharmaceuticals announced a study of phase 3 clinical trials for DKF-313 and Dutasteride. This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia. This study is conducted to access whether DKF-313 once daily for 48 weeks is superior to dutasteride 0.5 mg once daily and tadalafil 5 mg once daily each in improving BPH-LUTS as measured by changes in IPSS total scores.
  • October 2023: Boston Scientific Corporation announced a study of phases and clinical trials for alpha blocker and 5-alpha reductase inhibitor. The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
  • October 2023: Elpen Pharmaceuticals announced a study of phases and clinical trials for Patients with Benign Prostate Hyperplasia. The aim of the study was to investigate the benefits of combination therapy (dutasteride-tamsulosin) compared to monotherapy in terms of improvement of symptoms and long-term results (AUR and surgery), in men with moderate to severe BPH. The primary endpoint in the two years since the start of the study was the change in the IPSS score, while the primary endpoint, after four years of treatment, was the time until the long-term results manifested (i.E. AUR or CF surgery) as well as the percentage of participants who were led to them. Patients were at least 50 years old with a prostate tumor ≥30 cm3 and a PSA level ≥ 1.5 ng / mL. 4838 men (39) participated in this study. 
  • Discover more about therapies set to grab major Benign Prostatic Hyperplasia Market Share @ Benign Prostatic Hyperplasia Market Size

    Benign Prostatic Hyperplasia Overview

    Benign prostatic hyperplasia—also called BPH—is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention—the inability to empty the bladder completely—cause many of the problems associated with benign prostatic hyperplasia.

    Benign Prostatic Hyperplasia Epidemiology Segmentation in the 7MM

  • Total Benign Prostatic Hyperplasia Prevalent Cases
  • Benign Prostatic Hyperplasia Age-specific Prevalent Cases
  • Benign Prostatic Hyperplasia Diagnosed and Treatable Cases
  • Download the report to understand which factors are driving Benign Prostatic Hyperplasia Epidemiology Trends @ Benign Prostatic Hyperplasia Epidemiological Insights

    Benign Prostatic Hyperplasia Treatment Market

    The Benign Prostatic Hyperplasia treatment includes watchful waiting, medical therapies, minimally invasive surgery, and surgery. Watchful waiting is the recommended strategy for patients with BPH who have mild symptoms and for those with moderate-to-severe symptoms who are not bothered by their symptoms and are not experiencing complications of BPH. Medical therapies for the treatment of BPH include alpha-blockers, phosphodiesterase-5 inhibitors, 5-alpha reductase inhibitors, and combination medications.

    Benign Prostatic Hyperplasia Therapeutics Market

    The key driver for the Benign Prostatic Hyperplasia market is an increase in the cases of risk factors such as obesity, heart and circulatory disease, type 2 diabetes, a rise in the geriatric population along with the expected approval of emerging therapies such as Vibegron (Urovant Sciences, DKF-313 (Dongkook Pharmaceutical), and others. The Benign Prostatic Hyperplasia pipeline brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.

    To know more about Benign Prostatic Hyperplasia Treatment options, visit @ Benign Prostatic Hyperplasia Drugs

    Benign Prostatic Hyperplasia Market Insights

    Vibegron by Urovant Sciences and DKF-313 by Dongkook Pharmaceutical are eagerly anticipated emerging Benign Prostatic Hyperplasia therapies pending approval. The limited Benign Prostatic Hyperplasia drug pipeline can be attributed to the condition's complex pathophysiology, rigorous regulations, established treatments, market competition, safety concerns, and prioritization of resources for more critical conditions. These challenges collectively contribute to the scarcity of new Benign Prostatic Hyperplasia treatments.

    Benign Prostatic Hyperplasia Emerging Therapy Assessment

    Pharmaceutical companies worldwide are dedicated to pioneering innovative Benign Prostatic Hyperplasia treatment approaches with a track record of significant progress. Prominent industry leaders, including Urovant Sciences, Dongkook Pharmaceutical, and others are actively engaged in the development of therapies to address Benign Prostatic Hyperplasia (BPH).

    Learn more about the Benign Prostatic Hyperplasia Pipeline Therapies in clinical trials @ Benign Prostatic Hyperplasia Market Landscape

    Scope of the Benign Prostatic Hyperplasia Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Benign Prostatic Hyperplasia Companies- Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., and others.
  • Benign Prostatic Hyperplasia Pipeline Therapies- Tadalafil, Alpha1 Blocker, Tamsulosin OCAS, GV1001, Tamsulosin Hydrochloride Capsules, Silodosin and others.
  • Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia Market Drivers and Barriers
  • Benign Prostatic Hyperplasia Market Access and Reimbursement, Unmet Needs, and Future Perspectives
  • Discover more about Benign Prostatic Hyperplasia Drugs in development @ Benign Prostatic Hyperplasia Ongoing Clinical Trials Analysis

    Table of Content

  • Report Introduction
  • Benign Prostatic Hyperplasia Executive Summary
  • Benign Prostatic Hyperplasia Market Share at a glance
  • Benign Prostatic Hyperplasia Market Disease Background and Overview
  • Benign Prostatic Hyperplasia Patient Journey
  • Benign Prostatic Hyperplasia Epidemiology and Patient Population
  • Country Wise: Epidemiology of Benign Prostatic Hyperplasia
  • Current Benign Prostatic Hyperplasia Treatment and Medical Practices
  • Benign Prostatic Hyperplasia Marketed Drugs
  • To be continued in the report…

  • Benign Prostatic Hyperplasia Unmet Needs
  • Benign Prostatic Hyperplasia Emerging Therapeutics
  • Benign Prostatic Hyperplasia Market Size
  • Region-Wise Benign Prostatic Hyperplasia Market Size
  • Benign Prostatic Hyperplasia Market Drivers
  • Benign Prostatic Hyperplasia Market Barriers
  • SWOT Analysis
  • KOL Views
  • Reimbursement and Benign Prostatic Hyperplasia Market Access
  • Appendix
  • Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight
  • List of Top Selling Market Research Reports in 2023

    Defibrillators MarketPulse Oximeters MarketAnterior Cruciate Ligament Injuries MarketImage Guided Surgery Devices MarketMalt Lymphoma MarketAge-related Macular Degeneration MarketCritical Limb Ischemia MarketAirway Stent Market MarketAngioedema MarketAutomated External Defibrillators MarketHelicobacter Pylori Infection MarketPolycythemia Vera MarketAdult Growth Hormone Deficiency MarketAnemia In Ckd MarketAsmd MarketBile Duct Neoplasm MarketHearing Implants MarketHelicobacter Pylori Infections MarketIntracranial Pressure Monitoring Devices MarketNeurostimulation Devices MarketPolycythemia MarketPrefilled Syringes MarketVascular Access Devices MarketBlood Glucose Monitoring Systems MarketBronchial Spasms MarketCardiac Resynchronization Therapy Device MarketChemotherapy-induced Peripheral Neuropathy MarketChronic Obstructive Pulmonary Disease Copd MarketDeep Vein Thrombosis MarketHemodynamic Monitoring Systems MarketNeurovascular Devices MarketOphthalmic Imaging Equipment MarketSurgical Stapling Devices MarketTreatment Resistant Depression Market

    About Us

    DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions. 

    Contact Us

    Yash Bhardwaj

    info@delveinsight.Com






    Comments

    Popular posts from this blog

    Sentinel lymph node biopsy: What cancer patients should know

    Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

    Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer - RSNA Publications Online